orphan drug - Robuta Search

https://www.mabwell.com/en/news_info/id-132.html FDA Grants Orphan Drug Designation to 9MW3011 Mabwell is an innovation-driven biopharmaceutical company with end-to-end capabilities from drug discovery to commercialization. We are committed to provide... orphan drug designation fda grants https://amyloidosisnewstoday.com/news/nordsummit-orphan-drug-act-working-advance-rare-disease-treatments-fda-says/ #NORDsummit - Orphan Drug Act Is Working to Advance Rare Disease Treatments, FDA Says Apr 9, 2018 - FDA officials defended the Orphan Drug Act at the NORD Summit, crediting it with "spurring rare disease development" and calling price abuse claims untrue. orphan drug act rare disease working advance treatments https://www.drholzman.com/corneal-cross-linking-gets-second-orphan-69059/ Corneal Cross-linking gets second orphan drug status approval - drholzman.com Dec 8, 2011 - Dr. Holzman is gearing up to bring corneal cross-linking to Tysons Corner soon. He will be one of the principal investigators in a clinical study for corneal... orphan drug status cross linking corneal gets second https://www.pharmasalmanac.com/articles/pliant-therapeutics-receives-fda-orphan-drug-designation-for-lead-program-pln-74809-in-idiopathic-pulmonary-fibrosis Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic... Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis orphan drug designation pliant therapeutics receives fda https://www.biopharmaboardroom.com/news/11/1550/cabaletta-bios-caba-201-receives-fda-orphan-drug-designation-for-myositis.html Cabaletta Bio's CABA-201 Receives FDA Orphan Drug Designation for Myositis Cabaletta Bio's CABA-201 Receives FDA Orphan Drug Designation for Myositis orphan drug designation cabaletta bio receives fda https://explore.nemo.money/en/orphan-drug-moats-leaders-in-rare-disease 17 Orphan Drug Stocks After PTC Therapeutics FDA PTC Therapeutics' FDA rejection may benefit established orphan drug companies. Review 17 rare disease stocks with approved therapies. orphan drug ptc therapeutics stocks fda https://www.partnertx.com/zenocutuzumab%E2%80%91zbco-receives-fda-orphan-drug-designation-for-treatment-of-cholangiocarcinoma/ Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma –... Designation strengthens BIZENGRI® development program in rare cholangiocarcinoma LEXINGTON, Mass. —February 5, 2026—Partner Therapeutics, orphan drug designation receives fda treatment cholangiocarcinoma https://www.internationalfoodservicesreporter.com/article/945740502-leads-biolabs-pd-l1-4-1bb-bispecific-antibody-opamtistomig-lbl-024-granted-orphan-drug-designation-in-japan-further-expanding-global-regulatory Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug... bispecific antibody orphan drug leads biolabs lbl https://www.cancernetwork.com/view/atg-022-receives-fda-orphan-drug-designation-for-gastric-pancreatic-cancers ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers | CancerNetwork Oct 8, 2026 - Claudin 18.2–targeting antibody-drug conjugate ATG-022 is under assessment as part of the phase 1 CLINCH study in patients with advanced or metastatic solid... orphan drug designation pancreatic cancers atg receives fda https://forbion.com/dk/news-insights/news/azafaros-receives-fda-orphan-drug-designation-for-az-3102-in-gm2-gangliosidosis/ Azafaros Receives FDA Orphan Drug Designation | Forbion Azafaros B.V. today announced that the FDA has granted Orphan Drug Designation (ODD) for AZ-3102, a novel oral small molecule. orphan drug designation receives fda https://www.terrapinn.com/conference/world-orphan-drug-congress-asia/speaker-catherine-JAYASURIYA.stm Catherine Jayasuriya | Orphan Drug Congress Asia Catherine Jayasuriya - Conference where pharmas, patient groups, government and experts to join the discussion on providing proper medical for rare disease... orphan drug catherine jayasuriya congress asia https://www.legislation.gov.au/C2016G00286/asmade/downloads Designation of Chenodeoxycholic acid as an orphan drug by Link Healthcare - Federal Register of... chenodeoxycholic acid orphan drug federal register designation healthcare https://www.ithanet.eu/latest-information/news/imara-receives-orphan-drug-designation-for-imr-687-for-treatment-of-beta-thalassemia Imara Receives Orphan Drug Designation for IMR-687 for Treatment of β-Thalassemia orphan drug designation imara receives imr treatment https://healthcarejournaloregon.com/article/854568470-aavantgarde-announces-fda-orphan-drug-designation-and-uk-cta-approval-for-aavb-039-for-the-treatment-of-stargardt-disease AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the... orphan drug designation announces fda cta approval https://healthnewswire.com/press-release/neuroene-therapeutics-announces-orphan-drug-designation-granted-by-fda-for-dravet-syndrome-treatment-nt102-301411587/ Neuroene Therapeutics Announces Orphan Drug Designation Granted by FDA for Dravet Syndrome... CHARLESTON, S.C., Oct. 29, 2021 /PRNewswire/ — Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the orphan drug designation dravet syndrome therapeutics announces granted https://www.khondrion.com/news/khondrion-granted-orphan-drug-designation-for-kh176-for-the-treatment-of-midd-from-european-commission Khondrion | Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from... Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission... orphan drug designation the treatment granted midd https://pharmaceutical-business-review.com/news/timbers-tmb-001-ec-xlri/ Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI Mar 2, 2023 - Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI). orphan drug designation tmb receives treat xlri https://kffhealthnews.org/health-industry/drugmakers-manipulate-orphan-drug-rules-to-create-prized-monopolies/ Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies - KFF Health News Apr 18, 2026 - Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed... kff health news orphan drug to create drugmakers manipulate https://psynews.com/pharmadrug-announces-first-fda-orphan-drug-designation-of-dmt-for-the-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation/ PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of... Toronto, Ontario–(Newsfile Corp. – April 28, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“ PharmaDrug” or the “Company“), a specialty pharmaceutical... orphan drug designation for the announces first fda https://newsramp.com/blockchain/txn_detail/b931a7a21236764aec9a1a27331c22be Blockchain Registration Record for — FDA Grants Orphan Drug Status to Lantern Pharma's LP-284 for... NewsRamp registers all news stories on the blockchain to enhance reader trust and establish content provenance. Lantern Pharma receives FDA Orphan Drug... orphan drug status blockchain registration record fda https://www.gunpowderalerts.com/blog/fda-orphan-drug-approvals-2026-09-02 Orphan Drug Approvals — September 02, 2026 Sep 3, 2026 - During the period of September 2, 2026, the FDA approved four orphan-designated drugs, all classified as 'Other' (non-NME, non-biosimilar,... orphan drug approvals september https://www.partnertx.com/partner-therapeutics-receives-orphan-drug-designation-for-leukine-sargramostim/ Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim) – Partner... LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the orphan drug designation partner therapeutics receives sargramostim https://www.pressrelease.com/news/nx-development-corp-is-granted-orphan-drug-designation-status-by-us-22260331 NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian... orphan drug designation us fda development corp granted https://www.verahealth.ai/ja/news/pemphigus-vulgaris-resecabtagene-autoleucel-receives-fda-orphan-drug-designation Pemphigus vulgaris: resecabtagene autoleucel receives FDA orphan drug designation - Vera Health ニュース FDA OOPD listing shows designation granted March 14, 2026 for pemphigus vulgaris, signaling regulatory momentum for a cell therapy approach but no orphan... orphan drug designation pemphigus vulgaris receives fda vera https://editscd.eu/events/world-orphan-drug-2024/ World Orphan Drug 2024 - EDITSCD orphan drug world https://www.terrapinn.com/conference/world-orphan-drug-congress-asia/speakers.stm Speaker list | Orphan Drug Congress Asia Speaker list - Conference where pharmas, patient groups, government and experts to join the discussion on providing proper medical for rare disease patients orphan drug speaker list congress asia https://www.cureepilepsy.org/news/therapy-that-targets-underlying-cause-of-dravet-syndrome-gets-orphan-drug-status/ Therapy That Targets Underlying Cause of Dravet Syndrome Gets Orphan Drug Status – CURE Epilepsy Jun 18, 2024 - Therapy That Targets Underlying Cause of Dravet Syndrome Gets Orphan Drug StatusAugust 8, 2019The FDA has granted Orphan Drug designation to STK-001 (Stoke T... orphan drug status dravet syndrome therapy targets underlying https://www.ibtimes.co.uk/mustang-bio-stock-jumps-180-after-fda-grants-orphan-drug-status-brain-cancer-drug-1737772 Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug | IBTimes UK Jul 8, 2025 - Mustang Bio stock surged over 180% on Monday after the FDA granted its brain cancer drug candidate an orphan drug designation. orphan drug status mustang bio brain cancer stock jumps https://petrieflom.law.harvard.edu/tag/orphan-drug-incentives/ orphan drug incentives - Petrie-Flom Center orphan drug incentives petrie flom center https://pharma-fakten.de/news/1203-deutsche-orphan-drug-regelung-ein-erfolgsmodell/ Deutsche Orphan Drug-Regelung: Ein Erfolgsmodell - Pharma Fakten Jun 2, 2022 - „Zu teuer“, „zu wenig nachweisbarer Nutzen“: Das sind nur zwei der Kritikpunkte an Arzneimitteln gegen seltene Erkrankungen. Aktuell mehren sich die Stimmen,... orphan drug deutsche regelung ein pharma https://www.pharmtech.com/view/ionis-pharmaceuticals-receives-orphan-drug-designation-httrx Ionis Pharmaceuticals Receives Orphan Drug Designation for HTTRx | Pharmaceutical Technology Oct 8, 2026 - Ionis Pharmaceuticals receives orphan drug designation for HTTRx for the treatment of Huntington’s disease. orphan drug designation ionis pharmaceuticals receives technology https://www.federalregister.gov/documents/2013/06/12/2013-13930/orphan-drug-regulations Federal Register :: Orphan Drug Regulations Jun 12, 2013 - The Food and Drug Administration (FDA) is issuing final regulations amending the 1992 Orphan Drug Regulations issued to implement the Orphan Drug Act. These... federal register orphan drug regulations https://www.biospace.com/avidity-biosciences-receives-fda-orphan-drug-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-in-people-with-mutations-amenable-to-exon-44-skipping Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne... Aug 15, 2023 - Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1044, the company's... orphan drug designation avidity biosciences receives fda https://friedreichsataxianews.com/news/elamipretide-designated-fda-orphan-drug-fa-trial-starts/ Elamipretide for FA Wins FDA Orphan Drug Status, Phase 2 Trial Starts Apr 6, 2022 - Stealth BioTherapeutics‘ lead candidate elamipretide for the treatment of Friedreich’s ataxia was granted orphan drug status by the U.S. FDA. orphan drug status elamipretide wins fda phase https://www.thefdalawblog.com/2015/02/the-2014-numbers-are-in-fdas-orphan-drug-program-shatters-records/ The 2014 Numbers Are In: FDA’s Orphan Drug Program Shatters Records Oct 12, 2017 - By Kurt R. Karst – Earlier this month in a post concerning the Orange Book we mentioned our love of data and discussed how solid figures can reveal some... are in orphan drug numbers program shatters https://twolabs.com/orphan-diseases-open-opportunity-for-pharma-biotech-drug-developers/ Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers - Two Labs Pharma Services Jul 31, 2023 - As patents expire and generic competition increases, more drug companies are investing in the development of therapeutics for orphan diseases. orphan diseases for pharma open opportunity biotech https://www.globenewswire.com/news-release/2020/10/20/2110917/0/en/Pharmather-Files-for-FDA-Orphan-Drug-Designation-for-Ketamine-in-Parkinson-s-Disease.html Pharmather Files for FDA Orphan Drug Designation for TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”)... orphan drug designation files fda https://targedbiopharmaceuticals.com/news/tgd001-receives-orphan-drug-designation-in-europe/ TGD001 receives Orphan Drug Designation in Europe - TargED Oct 31, 2024 - TargED Biopharmaceuticals is thrilled to announce that the European Medicines Agency has granted Orphan Drug Designation for their innovative therapy, TGD001!... orphan drug designation in europe receives targed https://coyatherapeutics.com/coya-therapeutics-receives-orphan-drug-designation-from-the-fda-for-als001-an-autologus-treg-cell-therapy-for-the-treatment-of-als/ Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologus Treg Cell... Sep 28, 2022 - Completed Phase 2a trial with full data release by end of summer 2021 HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) — Coya Therapeutics, Inc. (Coya), a... orphan drug designation from the treg cell coya therapeutics https://www.fshdsociety.org/fr/2023/02/16/avidity-gets-orphan-drug-designation/ Avidity gets orphan drug designation - FSHD Society Feb 16, 2023 - Avidity Biosciences announced this week that it had received FDA Orphan Drug Designation for its experimental FSHD treatment, called AOC 1020. This does NOT... orphan drug designation avidity gets fshd society https://www.ferapharma.com/pressrelease/fera-obtains-orphan-drug-designation-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/ Fera Obtains Orphan Drug Designation for Naproxcinod for the Treatment of Sickle Cell Disease –... orphan drug designation sickle cell disease the treatment fera obtains https://www.lifesciencesipblog.com/orphan-drug-exclusivity-ode-fda-continues-its-attack-2 Orphan Drug Exclusivity (ODE) – FDA Continues Its Attack | Oblon Life Science orphan drug exclusivity life science ode fda continues https://hallrender.com/2013/07/24/hrsa-issues-340b-program-orphan-drug-final-rule-and-regulations/ HRSA Issues 340B Program Orphan Drug Final Rule and Regulations | Hall Render Nov 14, 2016 - Executive Summary On July 23, 2013, the Health Resources and Services Administration (“HRSA”) released a long-awaited final rule clarifying the scope of the... orphan drug hall render hrsa issues program https://certatherapeutics.com/certa-therapeutics-ft011-granted-us-fda-orphan-drug-designation-for-the-treatment-of-systemic-sclerosis/ Certa Therapeutics’ FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic... orphan drug designation us fda for the certa granted https://www.terrapinn.com/conference/world-orphan-drug-congress-asia/speaker-john-LIM.stm John Lim | Orphan Drug Congress Asia John Lim - Conference where pharmas, patient groups, government and experts to join the discussion on providing proper medical for rare disease patients john lim orphan drug congress asia https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=508615 Search Orphan Drug Designations and Approvals orphan drug search designations approvals https://www.usdailyledger.com/article/945740502-leads-biolabs-pd-l1-4-1bb-bispecific-antibody-opamtistomig-lbl-024-granted-orphan-drug-designation-in-japan-further-expanding-global-regulatory Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug... US Daily Ledger is an online news publication focusing on the United States: The most trusted news from the United States bispecific antibody orphan drug leads biolabs lbl https://journalforclinicalstudies.com/logistical-challenges-in-orphan-drug-trials-adopting-a-patient-centric-investigator-supportive-approach/ Logistical Challenges in Orphan Drug Trials - Adopting a Patient-Centric, Investigator-Supportive... May 14, 2015 - Clinical development programmes for orphan drugs present considerable financial and logistical challenges for pharmaceutical sponsors. Within this article we orphan drug logistical challenges trials adopting https://pompediseasenews.com/news/substrate-reduction-therapy-abx1100-fda-orphan-drug-status/ Substrate Reduction Therapy ABX1100 Granted FDA Orphan Drug Status | Pompe Disease News Aug 11, 2022 - ABX1100, Aro Biotherapeutics' experimental substrate reduction therapy for Pompe disease, has been granted orphan drug status by the FDA. substrate reduction therapy orphan drug status pompe disease granted fda https://adalta.com.au/adalta-receives-orphan-designation-lead-drug-candidate-targeting-patients-idiopathic-pulmonary-disease/ AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic... Jan 18, 2017 - MELBOURNE Australia, 18 January, 2017 – AdAlta Limited (ASX: 1AD), today announced it has received Orphan Drug Designation from the United States Food and Drug... orphan designation drug candidate receives lead targeting https://www.geneonline.com/fda-grants-orphan-drug-designation-to-fs2-for-potential-treatment-of-idiopathic-pulmonary-fibrosis/ FDA Grants Orphan Drug Designation to FS2 for Potential Treatment of Idiopathic Pulmonary Fibrosis... Dec 2, 2025 - The U.S. Food and Drug Administration (FDA) has granted […] orphan drug designation idiopathic pulmonary fibrosis fda grants potential https://arsacs.com/the-foundation-at-the-2025-world-orphan-drug-congress/ The Foundation at the 2025 World Orphan Drug Congress - ARSACS Apr 10, 2026 - From April 22 to 24, the Ataxia Charlevoix-Saguenay Foundation was present at the World Orphan Disease Congress (WODC), a major event gathering global leaders the foundation orphan drug world congress arsacs https://www.wendywalk.org/blog/2021/8/6/fda-grants-orphan-drug-status-to-sotigalimab-for-patients-with-soft-tissue-sarcoma FDA Grants Orphan Drug Status to Sotigalimab for Patients With Soft Tissue Sarcoma — Wendy Walk —... An orphan drug designation has been granted to the CD40 agonistic monoclonal antibody, sotigalimab, for the treatment of patients with soft tissue sarcoma. orphan drug status soft tissue sarcoma for patients fda grants